Format

Send to

Choose Destination
J Enzyme Inhib Med Chem. 2013 Feb;28(1):95-104. doi: 10.3109/14756366.2011.636360. Epub 2011 Dec 3.

NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation.

Author information

1
Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA 19406, USA. greg.j.gatto@gsk.com

Abstract

NADPH oxidase isoform-2 (NOX2) generates reactive oxygen species (ROS) that contribute to neurodegenerative and cardiovascular pathologies. However, validation of NOX2 as a pharmacotherapeutic target has been hampered by a lack of mechanistically-defined inhibitors. Using cellular and biochemical assays, we explored previously reported inhibitors of ROS production (perhexiline, suramin, VAS2870 and two Shionogi patent compounds) as direct NOX2 inhibitors. All but suramin, which presumably lacks cell penetrance, inhibit cellular ROS production. However, only perhexiline and suramin inhibit biochemical NOX2 activity. Indeed, our data suggest that NOX2 inhibition by perhexiline may contribute significantly to its demonstrated cardioprotective effects. Inhibition of protein kinase CβII explains the cellular activity of the Shionogi compounds, whereas VAS2870 inhibits by an as-yet unidentified mechanism unrelated to direct NOX2 function or subunit assembly. These data delineate the mechanisms of action of these compounds and highlight their strengths and limitations for use in future target validation studies.

PMID:
22136506
DOI:
10.3109/14756366.2011.636360
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center